Literature DB >> 18212505

Endothelin-A receptor blockade increases nutritive skin capillary circulation in patients with type 2 diabetes and microangiopathy.

Magnus Settergren1, John Pernow, Kerstin Brismar, Gun Jörneskog, Majid Kalani.   

Abstract

AIMS: Endothelin-1 levels are elevated in patients with type 2 diabetes mellitus and may contribute to impaired microvascular function. We investigated the effect of selective endothelin-A (ET(A)) receptor blockade (BQ123) on skin microcirculation in patients with type 2 diabetes and albuminuria.
METHODS: Ten type 2 diabetes patients and 8 non-diabetic controls were investigated. Nutritive skin capillary circulation, investigated by videophotometric capillaroscopy, and total skin microcirculation, assessed by laser Doppler flux-metry (LDF), were studied during intra-arterial infusion of saline for 15 min, followed by BQ123 infusion for 60 min.
RESULTS: Following BQ123 infusion there was a significant increase in resting capillary blood cell velocity (CBV) in patients with type 2 diabetes from 0.24 (0.20-0.34) mm/s at baseline to 0.61 (0.46-0.88) mm/s at 60 min, but no significant change in the control subjects [0.55 (0.10-0.68) vs. 0.38 (0.13-0.88) mm/s; p < 0.005 for difference between groups]. Peak CBV following arterial occlusion and skin temperature increased significantly in the type 2 diabetes group but not in the control group during BQ123 infusion. There were no significant changes in LDF parameters during infusion of BQ123 in either group.
CONCLUSION: ET(A) receptor blockade improves nutritive skin capillary circulation in patients with type 2 diabetes and microangiopathy. (c) 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18212505     DOI: 10.1159/000113601

Source DB:  PubMed          Journal:  J Vasc Res        ISSN: 1018-1172            Impact factor:   1.934


  8 in total

1.  The endothelin receptor antagonist bosentan improves peripheral endothelial function in patients with type 2 diabetes mellitus and microalbuminuria: a randomised trial.

Authors:  A Rafnsson; F Böhm; M Settergren; A Gonon; K Brismar; J Pernow
Journal:  Diabetologia       Date:  2011-12-27       Impact factor: 10.122

2.  Obesity, type 2 diabetes, and impaired insulin-stimulated blood flow: role of skeletal muscle NO synthase and endothelin-1.

Authors:  Leryn J Reynolds; Daniel P Credeur; Camila Manrique; Jaume Padilla; Paul J Fadel; John P Thyfault
Journal:  J Appl Physiol (1985)       Date:  2016-10-27

3.  Effect of the dual endothelin receptor antagonist bosentan on untreatable skin ulcers in a patient with diabetes: a case report.

Authors:  Fátima Alvarez Reyes; Cristina Luna Gómez; Manuel Brito Suárez
Journal:  J Med Case Rep       Date:  2011-04-16

4.  Selective endothelin A-receptor blockade attenuates coronary microvascular dysfunction after coronary stenting in patients with type 2 diabetes.

Authors:  Nikolaos Ostlund Papadogeorgos; Mattias Bengtsson; Majid Kalani
Journal:  Vasc Health Risk Manag       Date:  2009-11-02

Review 5.  The importance of endothelin-1 for microvascular dysfunction in diabetes.

Authors:  Majid Kalani
Journal:  Vasc Health Risk Manag       Date:  2008

6.  Improved peripheral perfusion during endothelin--a receptor blockade in patients with type 2 diabetes and critical limb ischemia.

Authors:  Majid Kalani; John Pernow; Joakim Bragd; Gun Jörneskog
Journal:  Diabetes Care       Date:  2008-07       Impact factor: 19.112

7.  Endothelin-1 Mediates Brain Microvascular Dysfunction Leading to Long-Term Cognitive Impairment in a Model of Experimental Cerebral Malaria.

Authors:  Brandi D Freeman; Yuri C Martins; Oscar B Akide-Ndunge; Fernando P Bruno; Hua Wang; Herbert B Tanowitz; David C Spray; Mahalia S Desruisseaux
Journal:  PLoS Pathog       Date:  2016-03-31       Impact factor: 6.823

8.  Severely impaired microvascular reactivity in diabetic patients with an acute coronary syndrome.

Authors:  Nikolaos Östlund Papadogeorgos; Gun Jörneskog; Mattias Bengtsson; Thomas Kahan; Majid Kalani
Journal:  Cardiovasc Diabetol       Date:  2016-04-20       Impact factor: 9.951

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.